GILD Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Gilead Sciences looks like a good buy right now for a beginner-focused, long-term investor with $50,000-$100,000 to deploy. The stock has constructive technical momentum, positive analyst revisions, and a supportive long-term growth story from HIV leadership plus new pipeline/catalyst optionality. At the current pre-market level around $130.92, it is still below the highest bullish analyst targets and appears reasonable for a patient long-term allocation. I would rate it a buy now rather than waiting.
GILD is in a mildly constructive short-term trend. MACD histogram is positive and expanding, which supports improving momentum. RSI_6 at 41.2 is neutral, so the stock is not overbought and still has room to move higher. Moving averages are converging, suggesting a base-building phase rather than a strong downtrend. Price is pre-market at 130.92, just above the current reference price of 130.5, with pivot at 132.475. Near-term resistance sits at 135.974 and 138.136, while support is at 128.976 and 126.814. The technical setup is favorable for a long-term entry, though near-term upside may be gradual.
Recent catalysts are supportive. Gilead completed the acquisition of Tubulis for $3.15 billion, which strengthens oncology exposure and diversifies the growth profile. The company also renewed its five-year WHO collaboration, which is positive for reputation and global access. Analyst sentiment has improved: Jefferies initiated Buy at $180, Maxim upgraded to Buy with a $165 target, Truist kept Buy and raised its target, Citi raised its target and kept Buy, and Morgan Stanley remains Overweight. The broad message from Wall Street is that Gilead has durable HIV strength, improving pipeline value, and better growth visibility.
There are a few headwinds. RBC remains only Sector Perform and is more conservative on Yeztugo and Trodelvy long-term upside. Congress trading data shows one sale and no purchases in the last 90 days, which is a cautious signal. Hedge fund and insider activity are neutral with no strong accumulation trend. Also, the stock is near a technical pivot rather than in a strong breakout, so upside may not be immediate.
The latest quarter referenced by analysts is Q1 2026. Truist noted that Gilead delivered top- and bottom-line beats and raised FY26 revenue guidance, driven by HIV strength, especially Yeztugo. Analysts highlighted encouraging early persistency signals for Yeztugo and continued dominance in HIV. Maxim also expects base business growth to improve to 5%-6%, above prior expectations of 4%-5%. Overall, the latest quarter trend points to solid operating momentum and improving growth expectations.
Analyst sentiment has turned more bullish over the past several weeks. Multiple firms raised price targets, and several now recommend Buy/Overweight. Jefferies initiated at Buy with $180, Maxim upgraded to Buy with $165, Morgan Stanley is Overweight with targets moved up to $168-$175, Truist is Buy at $157, and Citi is Buy at $165. RBC is the main holdout with Sector Perform and a much lower $122 target. Wall Street pros overall are constructive on Gilead, mainly because of strong HIV cash flow, improving pipeline optionality, and a more favorable long-term growth setup.
